Cargando…

Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids

An innovative spectrofluorometric method was developed for the analysis of a recently FDA approved anti-hepatitis C velpatasvir (VELP). The developed method was relied on dispersive solid phase extraction (dSPE) using synergistic effect of reduced graphene oxide (RGO) and cobalt hydroxide nanopartic...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Wekil, Mohamed M., Ali, Hassan Refat H., Marzouk, Adel A., Ali, Ramadan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079717/
https://www.ncbi.nlm.nih.gov/pubmed/35542513
http://dx.doi.org/10.1039/c7ra13719b
_version_ 1784702618492207104
author El-Wekil, Mohamed M.
Ali, Hassan Refat H.
Marzouk, Adel A.
Ali, Ramadan
author_facet El-Wekil, Mohamed M.
Ali, Hassan Refat H.
Marzouk, Adel A.
Ali, Ramadan
author_sort El-Wekil, Mohamed M.
collection PubMed
description An innovative spectrofluorometric method was developed for the analysis of a recently FDA approved anti-hepatitis C velpatasvir (VELP). The developed method was relied on dispersive solid phase extraction (dSPE) using synergistic effect of reduced graphene oxide (RGO) and cobalt hydroxide nanoparticles (CHNPs) in addition to cloud point extraction (CPE) using polyethylene glycol 6000 (PEG 6000) as non-ionic surfactant. This method combines the merits of preconcentration and interferences elimination achieved by dSPE and CPE, respectively. All relevant parameters such as surfactant concentration, ionic strength, pH, incubation time and others were thoroughly investigated and optimized. Fluorometric detection of VELP was carried out at excitation wavelength of 350 nm and emission wavelength of 415 nm. Under the optimum conditions, a linear calibration curve was achieved in the range of 0.5–45 ng mL(−1). Limits of detection (LOD) and quantification (LOQ) based on three and ten times the standard deviation of the blank were 0.040 and 0.112 ng mL(−1), respectively. This method was successfully applied for determination of VELP in real samples such as tablets, human plasma and urine samples with good recoveries.
format Online
Article
Text
id pubmed-9079717
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90797172022-05-09 Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids El-Wekil, Mohamed M. Ali, Hassan Refat H. Marzouk, Adel A. Ali, Ramadan RSC Adv Chemistry An innovative spectrofluorometric method was developed for the analysis of a recently FDA approved anti-hepatitis C velpatasvir (VELP). The developed method was relied on dispersive solid phase extraction (dSPE) using synergistic effect of reduced graphene oxide (RGO) and cobalt hydroxide nanoparticles (CHNPs) in addition to cloud point extraction (CPE) using polyethylene glycol 6000 (PEG 6000) as non-ionic surfactant. This method combines the merits of preconcentration and interferences elimination achieved by dSPE and CPE, respectively. All relevant parameters such as surfactant concentration, ionic strength, pH, incubation time and others were thoroughly investigated and optimized. Fluorometric detection of VELP was carried out at excitation wavelength of 350 nm and emission wavelength of 415 nm. Under the optimum conditions, a linear calibration curve was achieved in the range of 0.5–45 ng mL(−1). Limits of detection (LOD) and quantification (LOQ) based on three and ten times the standard deviation of the blank were 0.040 and 0.112 ng mL(−1), respectively. This method was successfully applied for determination of VELP in real samples such as tablets, human plasma and urine samples with good recoveries. The Royal Society of Chemistry 2018-04-10 /pmc/articles/PMC9079717/ /pubmed/35542513 http://dx.doi.org/10.1039/c7ra13719b Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
El-Wekil, Mohamed M.
Ali, Hassan Refat H.
Marzouk, Adel A.
Ali, Ramadan
Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title_full Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title_fullStr Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title_full_unstemmed Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title_short Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids
title_sort enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis c drug velpatasvir in pharmaceutical tablets and body fluids
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079717/
https://www.ncbi.nlm.nih.gov/pubmed/35542513
http://dx.doi.org/10.1039/c7ra13719b
work_keys_str_mv AT elwekilmohamedm enhanceddispersivesolidphaseextractionassistedbycloudpointstrategypriortofluorometricdeterminationofantihepatitiscdrugvelpatasvirinpharmaceuticaltabletsandbodyfluids
AT alihassanrefath enhanceddispersivesolidphaseextractionassistedbycloudpointstrategypriortofluorometricdeterminationofantihepatitiscdrugvelpatasvirinpharmaceuticaltabletsandbodyfluids
AT marzoukadela enhanceddispersivesolidphaseextractionassistedbycloudpointstrategypriortofluorometricdeterminationofantihepatitiscdrugvelpatasvirinpharmaceuticaltabletsandbodyfluids
AT aliramadan enhanceddispersivesolidphaseextractionassistedbycloudpointstrategypriortofluorometricdeterminationofantihepatitiscdrugvelpatasvirinpharmaceuticaltabletsandbodyfluids